Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
FDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk people
03:26pm, Thursday, 16'th Mar 2023
Paxlovid is recommended for people over 50 or those with medical conditions like high blood pressure or diabetes that place them at a greater risk of Covid.
FDA committee says benefits outweigh risks for Pfizer's Paxlovid
03:16pm, Thursday, 16'th Mar 2023
A Food and Drug Administration advisory committee voted 16-1 that the benefits of Pfizer's PFE COVID antiviral Paxlovid outweigh the risks in adults who are at high risk of severe disease. The FDA is
Is Pfizer Stock A Buy Or A Sell On Its Looming $43 Billion Seagen Takeover?
09:40am, Thursday, 16'th Mar 2023
Is Pfizer stock a buy or a sell after the company announced its $43 billion plan to buy Seagen? Is PFE stock a buy or a sell?
FDA panel to meet Thursday to discuss full approval of Paxlovid
08:35am, Thursday, 16'th Mar 2023
A Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should grant full approval to Paxlovid, the antiviral pill developed by Pfizer PFE to treat high-risk C
Here's Why Pfizer Stock Is Looking Increasingly Attractive
05:52am, Thursday, 16'th Mar 2023
Pfizer has had a string of good news in recent weeks, including several positive regulatory decisions. These positive developments seem to be underappreciated by investors.
Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants
04:00pm, Wednesday, 15'th Mar 2023
Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.
Pfizer's Latest Acquisition Strengthens the Case for PFE Stock
12:01pm, Wednesday, 15'th Mar 2023
On March 13, 2023, Pfizer, Inc. (NYSE: PFE) announced it was merging with Seagen Inc. (NASDAQ: SGEN). Under terms of the definitive agreement, Pfizer will buy Seagen for $229 in cash per share.
Royalty Pharma raises FY2023 guidance after $475M Pfizer milestone payment
11:42am, Wednesday, 15'th Mar 2023
Royalty Pharma plc announced that it is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2.85 billion and $2.95 billion, up from $2.375 billion and $2.475 billion pre
Pfizer will have to pay rebates to Medicare for five drugs under Biden plan to lower Rx costs
10:04am, Wednesday, 15'th Mar 2023
Five of Pfizer's drugs will cost less for Medicare recipients starting next month as part of President Joe Biden's plan to lower prescription drug cost.
FDA updates authorization of BioNTech, Pfizer's bivalent booster for young children
08:39am, Wednesday, 15'th Mar 2023
The Food and Drug Administration on Tuesday said children between the ages of 6 months and 5 years old can now get a booster dose of BioNTech BNTX and Pfizer's PFE COVID-19 bivalent vaccine. The third
3 Vaccine Stocks to Watch for Their Post-Pandemic Moves
09:44pm, Tuesday, 14'th Mar 2023
During the Covid-19 pandemic, vaccine stocks shot up on the promise that they could end the lockdowns. Many vaccines were developed, but few were approved.
7 Undervalued Dividend Stocks for Your Must-Buy List
06:42pm, Tuesday, 14'th Mar 2023
With markets getting dragged down by another financial crisis, investors should seek safety. In fact, one of the best places for that is in undervalued dividend stocks.
FDA authorizes Pfizer's Covid omicron booster as fourth shot for kids under 5
06:07pm, Tuesday, 14'th Mar 2023
The FDA authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original shot.
Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition
04:46pm, Tuesday, 14'th Mar 2023
Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.
FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults
03:04pm, Tuesday, 14'th Mar 2023
FDA staff said Pfizer's clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease.
